What is it?
Petrelintide is an investigational, long-acting version of amylin, a natural hormone that helps signal fullness after eating.
Gathering the record
Loading the next view…
Relay is organizing the evidence and source boundaries.
Gathering the record
Relay is organizing the evidence and source boundaries.
Long-acting human amylin analogue
Petrelintide is a once-weekly amylin analogue designed to reduce appetite and body weight without GLP-1 receptor agonism. Phase 1 is peer reviewed and a 42-week Phase 2 trial has positive sponsor-reported results.
60-Second Overview
Start with what it is, why it matters, what research has shown, and what remains unknown. The science follows after the orientation.
Start here. These four answers explain why the compound matters before the page introduces the deeper science.
Petrelintide is an investigational, long-acting version of amylin, a natural hormone that helps signal fullness after eating.
Researchers are studying whether strengthening that fullness signal can change appetite and weight without directly using the better-known GLP-1 pathway. They are also testing petrelintide in diabetes and combination programs.
Two small peer-reviewed early trials found that weekly study administration produced measurable weight reduction over 6 to 16 weeks. A larger 42-week trial later reported a positive weight signal, but those results remain sponsor reported rather than fully peer reviewed.
Long-term maintenance, rare harms, possible differences between groups, Phase 3 performance, and the effect of combining petrelintide with other medicines remain unresolved. No approved product or independent-vial preparation standard exists.
The research depth, routes, studies, and primary sources below explain how Relay knows—and where the evidence stops.
Research context
Published research has investigated this compound using the following study designs.
These records explain what researchers did. They are not instructions, recommendations, or a transferable protocol.
Peer-reviewed early research evaluated petrelintide in adults with overweight or obesity to measure safety, exposure, and short-term weight change.
Reported study administration—not a recommendation.
Research at a glance
Evidence depth, confidence, and route context explain how Relay knows—not what anyone should do.
Two Phase 1 trials, Phase 2 obesity, and ongoing metabolic studies.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
The largest result remains sponsor-reported.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: The randomized cohorts were small and followed participants for only 6 or 16 weeks. Early study material does not establish long-term outcomes, an approved regimen, or preparation rules for independent vials. Amounts shown describe cited research exposure—not a dosage recommendation.
Detailed evidence
Start with the strongest supported conclusion and its main uncertainty. Claim-level records below show how the evidence changes by question, population, route, formulation, and study design.
Two peer-reviewed randomized Phase 1 trials plus the 493-participant ZUPREME-1 Phase 2 obesity trial reported by the sponsor.
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
Full Phase 2 publication, sex-related response differences, longer-term maintenance, combination performance, Phase 3 outcomes, and rare-event safety.
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
Questions people bring to the evidence
Research questions—not promises of benefit.
The estimated half-life was about 10 days and the largest 16-week mean loss was 8.6%.
Mean reduction reached 10.7% in the best-performing arm versus 1.7% placebo.
Women reportedly lost more weight than men in ZUPREME-1.
Ongoing trials do not establish benefit.
Its appetite and weight biology comes through amylin-receptor signaling.
Mechanisms
Petrelintide is a long-acting analogue of human amylin. Two randomized Phase 1 studies reported an approximately 10-day half-life and weight reduction up to 8.6% after 16 weeks, with mostly mild gastrointestinal adverse events. In the 493-participant ZUPREME-1 Phase 2 trial, Roche reported mean weight reduction up to 10.7% at 42 weeks versus 1.7% with placebo. The sponsor highlighted a low vomiting rate and no gastrointestinal discontinuations in the maximally effective arm, but a sex difference in weight response and the absence of a peer-reviewed Phase 2 paper remain important uncertainties. Diabetes and combination studies are ongoing.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Two randomized, placebo-controlled multiple-dose trials
Adults with overweight or obesity
Petrelintide had an approximately 10-day half-life and produced mean weight reduction up to 8.6% at 16 weeks.
Study administration: Once-weekly subcutaneous petrelintide or placebo
Limitations: Small early-phase cohorts cannot define long-term efficacy or uncommon harms.
Randomized study in type 2 diabetes
Adults with type 2 diabetes and overweight or obesity
ZUPREME-2 is evaluating metabolic effects in type 2 diabetes.
Study administration: Weekly petrelintide or comparator
Limitations: No completed results were available.
Randomized, double-blind, placebo-controlled dose-ranging trial
Adults with overweight or obesity
The sponsor reported mean weight reduction up to 10.7% versus 1.7% with placebo.
Study administration: Five weekly petrelintide dose regimens or placebo
Limitations: Full peer-reviewed Phase 2 methods and results were not available at cutoff.
Official registry record for ZUPREME-1
Adults with overweight or obesity
The registry confirms the randomized Phase 2 design and population.
Study administration: Weekly petrelintide or placebo
Limitations: The registry does not independently establish the reported effect size.
Safety snapshot
No source-qualified adverse-event pattern is represented in the current record.
Evidence boundaryHuman exposure is present, but the record is not detailed enough to characterize a reliable adverse-event pattern.
The current record does not support a reliable common-versus-uncommon frequency split.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
No source-qualified compound-specific warning or contraindication is encoded in the current record.
Evidence boundaryInvestigational — Phase 2 obesity evidence Full Phase 2 publication, sex-related response differences, longer-term maintenance, combination performance, Phase 3 outcomes, and rare-event safety.
The current record does not identify a reliable compound-specific pattern of events that caused study discontinuation.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
No compound-specific patient-facing urgent-action threshold is established in the current Relay record.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
2026-04-01 · PMID 42017294 · DOI 10.1111/dom.70753
2026-03-05
2025-04-01 · NCT06926842
2024-11-01 · NCT06662539